Avalo Therapeutics (AVTX) Acquisitions (2017 - 2024)
Avalo Therapeutics posted quarterly Acquisitions of $356000.0 for Q1 2024, up 35599900.0% on a QoQ basis from $1.0 in Q1 2018.
Avalo Therapeutics (AVTX) has 3 years of Acquisitions data on file, last reported at $356000.0 in Q1 2024.
- For the quarter ending Q1 2024, Acquisitions changed N/A year-over-year to $356000.0; the trailing twelve-month figure through Dec 2024 stood at $356000.0 (changed N/A YoY), and the FY2024 full-year result was $356000.0, changed N/A from the prior year.
- Acquisitions for Q1 2024 stood at $356000.0, up from $1.0 in the prior quarter.
- Across five years, Acquisitions topped out at $356000.0 in Q1 2024 and bottomed at $356000.0 in Q1 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 356,000.00 |
| Mar 31, 2018 | 1.00 |
| Dec 31, 2017 | 18.89 Mn |